Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Supply Chain
Awards
CRO Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Supply Chain
Awards
CRO Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
PARP inhibitor
Pharma
J&J PARP combo Akeega nabs new FDA nod in prostate cancer niche
Akeega is the first precision medicine combo that can treat patients with BRCA2-mutated metastatic castration-sensitive prostate cancer.
Zoey Becker
Dec 15, 2025 12:14pm
FDA advisors unanimously reject Pfizer's Talzenna expansion bid
May 22, 2025 10:20am
AstraZeneca and Merck's Lynparza set to 'dominate' PARP market
Apr 24, 2024 8:23am
EU signs off on Merck and AZ's Lynparza after FDA delays ruling
Dec 21, 2022 9:43am
FDA delays review on AZ and Merck's Lynparza in prostate cancer
Dec 15, 2022 9:51am
AZ, MSD tap sports to spark prostate cancer conversations
Dec 14, 2022 7:45am
